News

Millions earmarked to boost research into new life-saving products to address the global rise of drug-resistant bacteria

The UK Government’s Global Antimicrobial Resistance Innovation Fund (GAMRIF) and the Bill & Melinda Gates Foundation (BMGF) have joined the CARB-X partnership to support scientific research around the world to develop new vaccines, preventatives, and other products against drug-resistant bacterial infections, particularly among vulnerable populations in low- and middle-income countries.

Read More...

Company in the spotlight: Avivia B.V.

NADP supports R&D collaborations. To give further insights in companies active in this area, we have initiated the column “Company in the spotlight” issue. In our second edition, we speak with Dr. Hans Platteeuw, founder and CEO of Avivia B.V., a Nijmegen based company that supports pharmaceutical development for new and existing drugs including drug...

Read More...

Dutch researchers report on novel antimicrobial peptide to combat drug-resistant bacteria and biofilms

Researchers from the Leiden University Medical Center (LUMC), Academic Medical Center (AMC) and the Association of Dutch Burn Centers have published on the use of antimicrobial peptide SAAP-148 to combat drug-resistant bacteria and biofilms in the latest edition of the scientific journal Science Translational Medicine.

Read More...

Benefit Call open for Belgium-Netherlands Funding of International Trials

The Belgian Health Care Knowledge Centre (KCE) and ZonMw, the Netherlands Organisation for Health Research and Care innovation, invest a maximum of 6 million euros in a joint programme under the name ‘BeNeFIT’.

Read More...

Science and industry work together on affordable alternatives to antibiotics

Almost fifty scientists and twenty companies will work on the development of new antibiotics and alternatives to antibiotics, which must become available for the healthcare system for a fair and affordable price. The research is done in eight projects that have received the green light from NWO Domain Applied and Engineering Sciences (AES). Together with...

Read More...

Company in the spotlight: AGILeBiotics B.V.

NADP supports R&D collaborations. To give further insights in companies active in this area, we have initiated the column“Company in the spotlight” issue. In this first edition, we speak with Dr. Andreas Bastian, the CEO of AGILeBiotics B.V. This antimicrobial developing company was founded earlier this year and is a perfect candidate to kick-off this...

Read More...